Dr. Tania Fleitas Kanonnikoff
Emerging Investigator
Research Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors – InDeST
Presentation
Tania Fleitas Kanonnikoff, is a Doctor in Medicine and Surgery from FCM-UNA (Paraguay) , she was specialized in Medical Oncology at the Hospital Clínico y Universitario La Fe in Valencia and received her PhD from the Universidad Autónoma de Barcelona with honors. Since then(2011), she has worked as a medical oncologist and post-doctoral researcher at the Hospital Clínico Universitario de Valencia.
Her clinical work focuses on the care of patients with digestive tumors and collaborates in the development of experimental therapy within clinical trials with a personalized medicine approach, and her research work focuses on translational research centered on the study of the microenvironment of gastric cancer. She is currently leading a national multicenter project funded by the Instituto de Salud Carlos III focused on the study of biomarkers of sensitivity to immunotherapy in gastric cancer, she is the scientific coordinator of the European LEGACy Project, focused on the multi-omic characterization of gastric cancer in EU and LATAM cohorts as well as strategies at the 3 levels of prevention for gastric cancer, and she is the principal investigator of the AIDA project focused on the development of an artificial intelligence assistant for prevention strategies in gastric cancer. On the other hand, she leads the VERO-1 and VERO-2 projects with private funding, focused on the study of sporadic gastric tumors in young populations.
To highlight her research experience, she did a Fellowship in the Adam Bass Laboratory, DFCI, Boston-Massachusetts for one year (2016) to carry out a project focused on the microenvironment of gastric cancer.
Publications
How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Cabeza-Segura M, Garcia-Micò B, La Noce M, Nicoletti GF, Conti V, Filippelli A, Fleitas T, Cervantes A, Castillo J, Papaccio F. Current Opinion in Pharmacology. 2023 Feb 23;69:102348. doi: 10.1016/j.coph.2023.102348. PMID: 36842387
In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: 10.1016/j.esmoop.2022.100763. PMID: 36603523
Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental & Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: 10.1186/s13046-022-02591-z. PMID: 36604765
Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D’Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2023 Jan;49(1):21-28. doi: 10.1016/j.ejso.2022.09.012. PMID: 36184420
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):1005-1020. doi: 10.1016/j.annonc.2022.07.004. PMID: 35914639
In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: 10.1016/j.esmoop.2021.100352. PMID: 34920292
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. PMID: 36253523
The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O’Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: 10.1186/s12885-022-09689-9. PMID: 35692051
In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: 10.1016/j.esmoop.2021.100061. PMID: 33639602
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: 10.1038/s41416-021-01502-x. PMID: 34493820
Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: 10.1016/j.annonc.2021.05.795. PMID: 34033882
Projects
Title: An Artificially Intelligent Diagnostic Assistant for gastric inflammation. AIDA
Funding body: European Commission
Principal Investigator: Tania Fleitas Kanonnikoff
Duration: 2023 – 2026
Total budget: 1,138,750 (Total: 6,334,803.75)
Title: Perfil de biomarcadores inmunes como herramienta para la identificación de pacientes con cáncer gástricos subsidiarios de inmunoterapia
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Tania Fleitas Kanonnikoff
Duration: 2022 – 2024
Total budget: 208.120 €
Title: DIRUGEN: Diseño e investigación de nuevos compuestos de rutenio (III) basados en biomoléculas como potenciales agentes antitumorales
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: Francisco José Martínez Lillo, Tania Fleitas Kanonnikoff
Duration: 2021 – 2022
Total budget: 19.000 €
Title: Macrófagos asociados al tumor, angiogénesis tumoral y resistencia a las terapias en Cáncer Gástrico Difuso fenotipo Mesenquimal
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Tania Carolina Fleitas Kanonnikoff
Duration: 2019 – 2021
Total budget: 99.220 €